EQ Stock Price, Equillium Inc Quote, Chart

Market Summary

USD1.57+0.03

Market Closed

1.95%

EQ Stock Price

View Fullscreen

EQ RSI Chart

EQ Valuation

Market Cap

55.3M

Price/Earnings (Trailing)

-4.56

Price/Sales (Trailing)

1.46

EV/EBITDA

-3.98

Price/Free Cashflow

-2.45

EQ Price/Sales (Trailing)

EQ Profitability

EBT Margin

-30.64%

Return on Equity

-57.5%

Return on Assets

-27.82%

Free Cashflow Yield

-40.9%

EQ Fundamentals

EQ Revenue

Revenue (TTM)

37.9M

Rev. Growth (Yr)

20.39%

Rev. Growth (Qtr)

16.05%

EQ Earnings

Earnings (TTM)

-12.1M

Earnings Growth (Yr)

30.61%

Earnings Growth (Qtr)

-16.74%

Breaking Down EQ Revenue

Last 7 days

2.6%

Last 30 days

-12.3%

Last 90 days

-43.1%

Trailing 12 Months

166.1%

How does EQ drawdown profile look like?

EQ Financial Health

Current Ratio

1.91

EQ Investor Care

Shares Dilution (1Y)

2.44%

Diluted EPS (TTM)

-0.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	37.9M	0	0	0
2023	20.8M	25.9M	31.0M	36.1M
2022	0	0	0	15.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Equillium Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 08, 2023	rothman joel	acquired	5,106	0.58	8,804	chief development officer
Dec 08, 2023	zedelmayer christine	acquired	5,106	0.58	8,804	sr. vice president and coo
Dec 08, 2023	keyes jason a	acquired	5,106	0.58	8,805	chief financial officer
Jun 09, 2023	rothman joel	acquired	8,400	0.56	15,000	chief development officer
Jun 09, 2023	zedelmayer christine	acquired	8,400	0.56	15,000	sr. vice president and coo
Jun 09, 2023	keyes jason a	acquired	8,400	0.56	15,000	chief financial officer
Dec 09, 2022	rothman joel	acquired	4,546	1.19	3,821	chief development officer
Dec 09, 2022	keyes jason a	acquired	5,288	1.19	4,444	chief financial officer
Aug 29, 2022	keyes jason a	sold	-19,810	2.83	-7,000	chief financial officer
Jun 10, 2022	zedelmayer christine	acquired	16,711	1.85	9,033	sr. vice president and coo

Which funds bought or sold EQ recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	246	87,751	96,456	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-17,852	-	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-99.51	-44,841	707	-%
May 15, 2024	Royal Bank of Canada	reduced	-79.72	-	-	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	sold off	-100	-289,200	-	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	27,483	27,483	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	new	-	35,805	35,805	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-21.56	10,216	16,999	-%
May 15, 2024	Integrated Wealth Concepts LLC	unchanged	-	63,480	92,400	-%
May 15, 2024	ADAR1 Capital Management, LLC	added	2,958	454,470	459,170	0.10%

Are Funds Buying or Selling EQ?

Are funds buying EQ calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EQ

No. of Funds

Unveiling Equillium Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Jan 19, 2024	takeda pharmaceutical co ltd	5.2%	1,842,977	SC 13G
Mar 03, 2023	victory capital management inc	3.93%	1,352,210	SC 13G/A
Jan 31, 2023	victory capital management inc	12.20%	4,192,654	SC 13G/A
Feb 14, 2022	decheng capital management iii (cayman), llc	15.13%	4,447,308	SC 13G
Feb 01, 2022	victory capital management inc	14.04%	4,125,667	SC 13G/A
Feb 16, 2021	decheng capital global life sciences fund iv, l.p.	14.7%	4,271,423	SC 13D
Feb 03, 2021	victory capital management inc	11.32%	2,798,132	SC 13G/A
Feb 14, 2020	partner fund management, l.p.	0%	6	SC 13G/A
Jan 29, 2020	victory capital management inc	12.86%	2,233,724	SC 13G/A

Recent SEC filings of Equillium Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 11, 2024	DEFA14A	DEFA14A
Apr 11, 2024	DEF 14A	DEF 14A
Apr 11, 2024	ARS	ARS
Apr 01, 2024	PRE 14A	PRE 14A
Apr 01, 2024	8-K	Current Report
Mar 25, 2024	S-8	Employee Benefits Plan
Mar 25, 2024	8-K	Current Report
Mar 25, 2024	10-K	Annual Report

Peers (Alternatives to Equillium Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Equillium Inc News

Latest updates

Equillium Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Revenue	16.0%	10,689,000	9,211,000	8,870,000	9,124,000	8,879,000	-
Operating Expenses	8.6%	13,480,000	12,411,000	12,493,000	12,715,000	12,987,000	13,717,000
S&GA Expenses	-100.0%	-	3,227,500	3,519,000	3,105,000	3,715,000	5,192,000
EBITDA Margin	13.8%	-0.29	-0.34	-0.22	-0.65	-1.33	-3.89
Interest Expenses	-	-	-	-	259,000	232,000	271,500
Income Taxes	100.0%	-	-4,000	496,000	8,000	100,000	-
Earnings Before Taxes	-17.5%	-2,734,000	-2,326,000	-3,214,000	-3,335,000	-3,880,000	2,773,000
EBT Margin	13.3%	-0.31	-0.35	-0.25	-0.70	-1.39	-3.96
Net Income	-16.7%	-2,734,000	-2,342,000	-3,710,000	-3,343,000	-3,940,000	2,773,000
Net Income Margin	13.4%	-0.32	-0.37	-0.27	-0.70	-1.39	-3.96
Free Cashflow	-54.7%	-8,819,000	-5,699,000	-1,911,000	-6,217,000	-7,997,000	27,723,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-13.7%	44.00	51.00	55.00	59.00	72.00	78.00	49.00	62.00	74.00	85.00	92.00	100	107	85.00	92.00	44.00	50.00	56.00	63.00	58.00	63.00
Current Assets	-13.9%	42.00	49.00	54.00	57.00	70.00	77.00	47.00	60.00	72.00	83.00	92.00	100	107	85.00	92.00	44.00	50.00	55.00	63.00	58.00	63.00
Cash Equivalents	-50.2%	12.00	23.00	34.00	26.00	25.00	59.00	26.00	24.00	26.00	50.00	77.00	74.00	51.00	24.00	49.00	24.00	21.00	13.00	28.00	23.00	21.00
Net PPE	14.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-19.5%	23.00	28.00	31.00	32.00	43.00	46.00	20.00	22.00	22.00	19.00	17.00	15.00	15.00	16.00	14.00	13.00	14.00	14.00	14.00	4.00	3.00
Current Liabilities	-19.5%	22.00	28.00	28.00	25.00	32.00	32.00	15.00	15.00	13.00	9.00	8.00	5.00	7.00	7.00	5.00	3.00	4.00	4.00	4.00	4.00	3.00
Shareholder's Equity	-6.6%	21.00	23.00	24.00	27.00	29.00	32.00	28.00	40.00	53.00	67.00	76.00	85.00	92.00	70.00	78.00	31.00	36.00	42.00	49.00	54.00	59.00
Retained Earnings	-1.5%	-188	-185	-183	-179	-176	-172	-175	-161	-147	-109	-99.36	-89.07	-79.92	-70.92	-62.01	-55.41	-48.95	-41.11	-33.54	-27.53	-21.46
Additional Paid-In Capital	0.5%	209	208	207	206	205	204	203	202	200	177	175	174	172	141	140	86.00	85.00	83.00	82.00	82.00	81.00
Shares Outstanding	0%	35.00	35.00	35.00	35.00	34.00	34.00	34.00	33.00	34.00	29.00	29.00	29.00	27.00	25.00	-	-	-	-	-	-	-
Float	-	-	-	-	16.00	-	-	-	43.00	-	-	-	95.00	-	-	-	19.00	-	-	-	34.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-55.4%	-8,800	-5,664	-1,909	-6,215	-7,995	27,725	-13,065	-11,259	-12,134	-10,133	-7,010	-6,994	-7,944	-8,253	-4,921	-5,080	-6,370	-9,033	-4,696	-4,756	-4,464
Share Based Compensation	-7.1%	972	1,046	979	934	1,038	1,052	1,189	1,302	1,298	1,152	1,150	1,064	1,044	833	847	1,350	787	592	633	581	446
Cashflow From Investing	49.1%	-2,831	-5,566	10,985	15,000	-25,181	6,978	15,000	8,691	-11,985	-16,889	10,468	28,967	4,860	-17,036	-23,016	8,455	13,005	-5,330	-225	6,040	-2,651
Cashflow From Financing	-100.0%	-	79.00	-260	-7,618	-1,429	-1,356	-	-	-	225	174	698	29,964	11.00	53,063	96.00	775	-105	-	-	-
Buy Backs	-	-	-	260	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EQ Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 10,689	$ 8,879
Operating expenses:
Research and development	9,743	9,272
General and administrative	3,737	3,715
Total operating expenses	13,480	12,987
Loss from operations	(2,791)	(4,108)
Other income, net:
Interest expense		(232)
Interest income	439	639
Other expense, net	(382)	(179)
Total other income, net	57	228
Loss before income taxes	(2,734)	(3,880)
Income tax expense	0	60
Net loss	(2,734)	(3,940)
Other comprehensive income, net:
Unrealized (loss) gain on available-for-sale securities, net	(22)	96
Foreign currency translation gain	305	133
Total other comprehensive income, net	283	229
Comprehensive loss	$ (2,451)	$ (3,711)
Net loss per share, basic	$ (0.08)	$ (0.11)
Net loss per share, diluted	$ (0.08)	$ (0.11)
Weighted-average number of common shares outstanding, basic	35,254,752	34,414,149
Weighted-average number of common shares outstanding, diluted	35,254,752	34,414,149

EQ Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 11,568	$ 23,216
Short-term investments	20,717	17,650
Accounts receivable	5,048	3,735
Prepaid expenses and other current assets	5,147	4,748
Total current assets	42,480	49,349
Operating lease right-of-use assets	694	796
Property and equipment, net	361	315
Other assets	62	70
Total assets	43,597	50,530
Current liabilities:
Accounts payable	2,778	4,707
Accrued expenses	5,646	6,697
Current portion of deferred revenue	13,360	15,729
Current portion of operating lease liabilities	424	440
Total current liabilities	22,208	27,573
Long-term operating lease liabilities	295	384
Total liabilities	22,503	27,957
Commitments and contingencies
Stockholders' equity:
Common stock, $0.0001 par value; 200,000,000 shares shares authorized as of March 31, 2024 and December 31, 2023; 35,254,752 shares issued and outstanding as of March 31, 2024 and December 31, 2023	3	3
Additional paid-in capital	209,142	208,170
Accumulated other comprehensive income	423	140
Accumulated deficit	(188,474)	(185,740)
Total stockholders' equity	21,094	22,573
Total liabilities and stockholders' equity	$ 43,597	$ 50,530

About Equillium Inc

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California.

CEO	Mr. Bruce D. Steel C.F.A.
WEBSITE	https://equilliumbio.com
INDUSTRY	Biotechnology
EMPLOYEES	47

Equillium Inc Frequently Asked Questions

What is the ticker symbol for Equillium Inc? What does EQ stand for in stocks?

EQ is the stock ticker symbol of Equillium Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Equillium Inc (EQ)?

As of Fri May 17 2024, market cap of Equillium Inc is 55.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EQ stock?

You can check EQ's fair value in chart for subscribers.

What is the fair value of EQ stock?

You can check EQ's fair value in chart for subscribers. The fair value of Equillium Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Equillium Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EQ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Equillium Inc a good stock to buy?

The fair value guage provides a quick view whether EQ is over valued or under valued. Whether Equillium Inc is cheap or expensive depends on the assumptions which impact Equillium Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EQ.

What is Equillium Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, EQ's PE ratio (Price to Earnings) is -4.56 and Price to Sales (PS) ratio is 1.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EQ PE ratio will change depending on the future growth rate expectations of investors.